Mersana Therapeutics Total Assets 2016-2021 | MRSN

Mersana Therapeutics total assets from 2016 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Mersana Therapeutics Annual Total Assets
(Millions of US $)
2020 $273
2019 $108
2018 $79
2017 $131
2016 $105
2015 $0
Mersana Therapeutics Quarterly Total Assets
(Millions of US $)
2021-09-30 $218
2021-06-30 $254
2021-03-31 $248
2020-12-31 $273
2020-09-30 $290
2020-06-30 $311
2020-03-31 $96
2019-12-31 $108
2019-09-30 $122
2019-06-30 $139
2019-03-31 $149
2018-12-31 $79
2018-09-30 $94
2018-06-30 $107
2018-03-31 $116
2017-12-31 $131
2017-09-30 $143
2017-06-30 $85
2017-03-31 $0
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2015-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.462B $0.001B
Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $121.969B 7.71
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.359B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $7.214B 0.00
Arcus Biosciences (RCUS) United States $3.030B 0.00
Emergent Biosolutions (EBS) United States $2.347B 8.44
ADC Therapeutics SA (ADCT) Switzerland $1.505B 0.00
Myovant Sciences (MYOV) United Kingdom $1.429B 0.00
Zymeworks (ZYME) Canada $0.942B 0.00
Ambrx Biopharma (AMAM) United States $0.366B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09